Researchers develop blood test to detect lung cancer

Jul 31, 2006

Lung cancer is the leading cause of cancer death for both men and women in the United States and around the world, mainly because lung cancers are found in late stages and the best treatment opportunities already have been missed. In Kentucky, the incidence of lung cancer is 49 percent higher than the national rate. However, a new blood test being developed at the University of Kentucky could soon change all that.

For the past five years, Drs. Edward A. Hirschowitz and Li Zhong have led a team developing the blood test, which could potentially help detect lung cancer in early stages in people with high risk factors for developing the disease.

"Early detection of lung cancer is the key to improving survival," said Zhong, who was the lead author of a study appearing in the July issue of the Journal of Thoracic Oncology that described how the test is 90 percent accurate in correctly predicting non-small-cell lung cancer in patients years before any CT scan can detect it.

Although the researchers have received almost $1.5 million in funding for the development of the test from various sources, they recently received an additional $175,000 National Institutes of Health grant to transform the blood test into a format that real-world clinicians could easily use. And with further studies confirming the reliability of the new format, it could become the first blood test to predict cancer since the prostate specific antigen (PSA) test was introduced in the 1970s.

The multi-biomarker blood test, which works by identifying the body's own immune response to tumors, would help diagnose lung cancer at the earliest stage in those with high risk factors such as age, smoking and genetic history.

Globally, lung cancer is by far the biggest cancer killer, with 10 million people diagnosed each year. In the U.S. alone, the number of lung cancer deaths has risen for each of the past five years to nearly 164,000. The main reason for such a high fatality rate is that 85 percent of lung cancers are found in stages too advanced for best treatment opportunities, Zhong said. Half of all patients die within a year of diagnosis.

For the next two years, the UK research team will collaborate with the private biotechnology company 20/20 GeneSystems to develop the clinical application for the blood test.

"We are hoping in the next several years this test would become available to the public," Zhong said.

Source: University of Kentucky

Explore further: Analysis of spider venom reveals seven promising compounds with potential to relieve chronic pain

add to favorites email to friend print save as pdf

Related Stories

Deadly frog fungus dates back to 1880s, studies find

1 hour ago

A deadly fungus responsible for the extinction of more than 200 amphibian species worldwide has coexisted harmlessly with animals in Illinois and Korea for more than a century, a pair of studies have found.

Think twice about investing in own company

2 hours ago

Employees whose retirement plan is invested in stock of the company where they work do not pull out money as the firms approach financial distress, a recently released, but yet to be published paper, co-authored ...

Recommended for you

AHA: Many US adults taking action to reduce sodium intake

59 minutes ago

(HealthDay)—Many U.S. adults are taking action to reduce sodium intake, according to research presented at the American Heart Association's Epidemiology and Prevention/Lifestyle and Cardiometabolic Health ...

Anemia linked to adverse outcomes in atrial fibrillation

1 hour ago

(HealthDay)—For patients with atrial fibrillation receiving anticoagulant treatment, the presence of anemia is associated with increased risk of thromboembolic events, bleeding complications, and mortality, ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.